The Effect of Weight Loss and Metabolic Interventions on Recurrence After Atrial Fibrillation Ablation

Figures

• 

  Figure 1. A framework for comprehensive management to reduce recurrence after atrial fibrillation (AF) ablation. The left panel identifies core, modifiable contributors to post-ablation recurrence—obesity and epicardial adipose tissue (EAT). The central panel groups interventions into four categories: (1) lifestyle intervention (exercise, dietary modification, alcohol restriction); (2) bariatric surgery; (3) integrated risk-factor management; and (4) metabolic pharmacotherapy (SGLT2i and GLP-1RA). These interventions are supported by evidence of differing strength—from randomized trials to observational and mechanistic data—as detailed in Table 1; solid arrows denote interventions supported by randomized evidence and dashed arrows those resting on observational or mechanistic data. The right panel indicates the shared goal of reduced AF recurrence and improved clinical outcomes. The figure summarizes proposed relationships and is not intended to imply equivalent certainty across interventions. Abbreviations: AF: atrial fibrillation; EAT: Epicardial Adipose Tissue; GLP-1RA: Glucagon-Like Peptide-1 Receptor Agonist; SGLT2i: Sodium-Glucose Cotransporter 2 Inhibitor. Created in BioRender.…

• 

  Figure 2. Pathophysiological Mechanisms of Epicardial Adipose Tissue (EAT)-Mediated Atrial Remodeling. This schematic illustrates the proposed pathways through which hypertrophied and numerically increased EAT cells contribute to the pathogenesis of AF. The detrimental cross-talk between EAT and the underlying atrial myocardium is driven by three primary mechanisms: (1) Inflammation Cascade: Obesity-mediated signaling activates the NLRP3 inflammasome, which directly promotes atrial structural remodeling and fibrosis. (2) STING Pathway: The activation of STING triggers sterile inflammation, leading to mitochondrial damage and calcium overload. These intracellular disruptions cause significant alterations in the Atrial Effective Refractory Period (ERP). (3) Secretome: EAT functions as an active endocrine organ, releasing a variety of pro-inflammatory and pro-fibrotic substances (such as TGF-β1) and interacting with pathways like the Endothelin B receptor. This paracrine signaling ultimately results in profound electrophysiological alterations in the atrial tissue. Arrows (→) indicate activation or promotion; blunt-ended arrows (⊣) indicate inhibition. Colours are used for illustrative…

• 

  Figure 3. Distinct and Synergistic Mechanisms of SGLT2i and GLP-1RA Combination Therapy. This schematic illustrates the independent intracellular signaling pathways modulated by SGLT2i (left panel) and GLP-1 receptor agonists (right panel), which are proposed to converge on synergistic cardioprotective effects. The pathways depicted derive largely from preclinical and non-atrial experimental models and remain to be confirmed in the human atrium. The SGLT2i mechanism involves inhibition of the Sodium-Hydrogen Exchanger (NHE), leading to decreased phosphorylation of PLC and a subsequent reduction in IP3 production. This cascade ultimately modulates intracellular Ca2+ homeostasis and inhibits pro-fibrotic activity. Concurrently, the GLP-1RA mechanism inhibits Kv1.5 and Nav1.5 channels, thereby prolonging action potential duration. Furthermore, GLP-1RA activates the HRD1-Nrf2 axis, increasing Nrf2 protein expression and nuclear translocation, thereby reducing cellular apoptosis. When used as a Combination Therapy, these distinct pathways yield synergistic effects that significantly attenuate inflammation-related oxidative stress and reduce reactive oxygen species (ROS) levels. Arrows (→)…